Newsroom

Sorted by: Latest

-

Prometheus Announces Breakthrough e-Kerosene Pathway to Make Cost-Competitive SAF and Diesel from Electricity and Air    

SANTA CRUZ, Calif.--(BUSINESS WIRE)--Prometheus unveils breakthrough e-Kerosene pathway to make low-cost SAF and diesel from solar and air. The new pathway makes Fischer-Tropsch obsolete....
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Presto Appoints Former Dairy Queen CEO Chuck Mooty as Strategic Advisor

SAN MATEO, Calif.--(BUSINESS WIRE)--Presto Phoenix, Inc. (“Presto”), the leader in enterprise-grade Voice AI for quick-service restaurants (QSRs), today announced that Chuck Mooty, former CEO of Dairy Queen, had joined the company as a strategic advisor. "Chuck is a highly respected leader in the industry, and I have deep admiration for him. His family partnered with Berkshire Hathaway, which crystallized Dairy Queen’s iconic role in American culture, and Chuck served as CEO and Chairman for 8...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Unity Announces Fourth Quarter and Fiscal Year 2025 Financial Results Webcast

SAN FRANCISCO--(BUSINESS WIRE)--Unity (NYSE: U) announced today it will release fourth quarter and fiscal year 2025 financial results before the market opens on February 11, 2026, with a webcast to follow at 8:30 a.m. ET/5:30 a.m. PT. The webcast and financial results will be accessible at investors.unity.com. A replay of the webcast will also be available on Unity’s Investor Relations website. About Unity Software Inc. (Unity) Unity [NYSE: U] offers a suite of tools to develop, deploy, and gro...
-

Monnai Raises $12 Million in Equity Funding to Build the Global Standard for Identity and Risk Decisioning

LOS ANGELES--(BUSINESS WIRE)--Monnai announces a $12M funding round, led by Motive Partners, to scale its identity and risk data infrastructure....
-

Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s launched Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC), a generic equivalent of Extra-Strength Pataday® Once Daily Relief....
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...